Novozymes delivers resilient full-year results despite the COVID-19 pandemic and is confident about getting back to growth in 2021 - Seite 2

2020-highlights
Novozymes launched 18 products across business areas in 2020 and made good progress on the commercialization of the innovation in key platforms such as Freshness and Balancius.
Among others, the company reached a key milestone with its first internal Human Health product launch; BioFresh 4+. The Human Health business also advanced by two game-changing acquisitions.

In June, Novozymes acquired PrecisionBiotics Group to strengthen its Human Health business and advance its activities in the area of biological solutions for human oral and gut health. In December, Novozymes acquired US-based Microbiome Labs adding a strong position in the North American probiotics market and gaining access to the company’s network of health practitioners.

Financial guidance for 2021
Novozymes is guiding for 2-6% organic sales growth reflecting continued covid-19 related uncertainty but a gradual recovery in those markets that were negatively affected by the pandemic.

Sales in reported DKK are expected to be 1 percentage point less than the organic growth outlook of 2-6%.  Novozymes expects a reported EBIT margin in DKK of 25-26% including negative impact from currency and M&A-related effects of around 1 percentage point each.

Food, Beverages & Human Health and Grain & Tech Processing are expected to grow mid-single-digits while Bioenergy is expected to grow between mid-to-high single digits in 2021. The growth outlook for Household Care is low-single-digits following the strong performance in 2020. Agriculture, Animal Health & Nutrition is expected between flat to low-single-digit growth.

About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

NASDAQ OMX: NZYM-B • 6,500 employees • DKK 14,5 billion turnover • 30+ industries • 700+ products

Media Relations
Lina Danstrup,